Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAILOR: Individually Tailored Treatment for Advanced Cancers
NCT04801966Terminated
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Sep 2021
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Trial of trametinib, cobimetinib, binimetinib, alpelisib, vemurafenib and 10 more, sponsored by Peter MacCallum Cancer Centre. Started Sep 2021; status: terminated.
02
Drugs
trametinibcobimetinibbinimetinibalpelisibvemurafenib
Beyond the preview
Go deeper on NCT04801966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04801966.